- Active Surveillance
- Administrative Data
- Research Methods
- Clinical Therapeutics
- Population Health, Epidemiology and Biostatistics
- Health Services Policy/Pharmaceutical Policy
- Knowledge Translation/Implementation Science
- Other. PGx
- Professor of Paediatrics and Pharmaceutical Sciences, University of British Columbia
- Director, Pharmaceutical Outcomes and Policy Innovations Programme, Children’s and Women’s Health Centre of BC
- Senior Clinician Scientist, Child & Family Research Institute
Dr. Bruce Carleton earned his Bachelor of Pharmaceutical Sciences from Washington State University and his Doctor of Pharmacy from the University of Utah. In addition, Dr. Carleton completed his Residency in Clinical Pharmacy at the University of Utah followed by two Research Fellowships at the University of Minnesota. The first being in Experimental Pharmacotherapy, followed by another in Immunopharmacology (American College of Clinical Pharmacy / Sandoz Immunology Research Fellowship).
The central theme of Dr. Carleton’s research program, Pharmaceutical Outcomes and Policy Innovations (POPi), is the study of drug therapy with the goal of improving human health and quality of life. He is particularly interested in developing models for evaluating drug effectiveness, medication use models designed to improve patient health, and effective surveillance systems to improve the safe use of medication. He has a particular clinical interest in paediatric medicine, with specific emphases on asthma and the epidemiology and clinical management of adverse drug reactions. Another area of interest is the translation of knowledge to aid evidence-based drug policy development. POPi contributes to solving the international drug policy crisis on two levels: the public policy level (federal and provincial), and the clinical policy level. In this way the needs of government are served to manage drug budgets, the needs of clinicians to improve patient care, and the public need to understand and improve the effectiveness, safety and cost effectiveness of drugs.